Climb Bio (CLYM) Stock: Buy, Sell, or Hold?
CLYM - Climb Bio, Inc. Common Stock
$10.19
-0.35 (-3.32%)
âŧ
5d:
+3.77%
30d:
-14.3%
90d:
-20.33%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 05, 2026
11d
Get Alerted When CLYM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CLYM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CLYM is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CLYM is currently trading at $10.19, which is considered slightly low relative to its 30-day fair value range of $10.36 to $13.40.
Technical Outlook: Technically, CLYM is showing sideways momentum. Immediate support is located at $9.61, while resistance sits at $11.26. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $27.60 (+170.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CLYM is showing sideways momentum. Immediate support is located at $9.61, while resistance sits at $11.26. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $27.60 (+170.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$10.36 -
$13.40
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 170.9% below Wall St target ($27.60)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.36 -
$13.40
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$9.61
Resistance Level
$11.26
Current Trend
Sideways
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.16
Wall Street Target
$27.60
(+170.9%)
Share & Embed Analysis
Last updated: October 24, 2026 1:15 PM ET
Data refreshes hourly during market hours. Next update: 2:15 PM
Data refreshes hourly during market hours. Next update: 2:15 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLYM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
PRAX
Praxis Precision MedicinâĻ |
STRONG BUY
20 analysts |
$650 | 65 BUY |
|
INCY
Incyte Corporation |
HOLD
28 analysts |
$130 | 69 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
20 analysts |
$17 | 47 HOLD |
